CLINICAL TRIALS PROFILE FOR EVOBRUTINIB

Clinical Trials for Evobrutinib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02537028 ↗	MSC2364447C Phase 1b in Systemic Lupus Erythematosus	Completed	Merck KGaA	Phase 1	The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).
NCT02537028 ↗	MSC2364447C Phase 1b in Systemic Lupus Erythematosus	Completed	Merck KGaA, Darmstadt, Germany	Phase 1	The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).
NCT02537028 ↗	MSC2364447C Phase 1b in Systemic Lupus Erythematosus	Completed	EMD Serono Research & Development Institute, Inc.	Phase 1	The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).
NCT02784106 ↗	Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis	Completed	Merck KGaA	Phase 2	M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).
NCT02784106 ↗	Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis	Completed	Merck KGaA, Darmstadt, Germany	Phase 2	M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).

Clinical Trial Conditions for Evobrutinib

Condition Name

Condition Name
Intervention	Trials
Healthy	8
Relapsing-remitting Multiple Sclerosis	3
Rheumatoid Arthritis	2
Relapsing Multiple Sclerosis	2

Condition MeSH

Condition MeSH
Intervention	Trials
Sclerosis	5
Multiple Sclerosis	5
Multiple Sclerosis, Relapsing-Remitting	3
Lupus Erythematosus, Systemic	2

Clinical Trial Locations for Evobrutinib

Trials by Country

Trials by Country
Location	Trials
United States	81
Germany	18
Japan	11
Mexico	11
Argentina	8

Trials by US State

Trials by US State
Location	Trials
Massachusetts	8
Florida	5
California	5
Texas	5
Michigan	4

Clinical Trial Progress for Evobrutinib

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	4
Phase 1	11

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	10
Active, not recruiting	3
Terminated	3

Clinical Trial Sponsors for Evobrutinib

Sponsor Name

Sponsor Name
Sponsor	Trials
Merck KGaA, Darmstadt, Germany	11
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	10
EMD Serono Research & Development Institute, Inc.	9

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	38